MedTrace Logo

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23

NCT03802292 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2021-03-03

No results posted yet for this study

Summary

This study is to test the safety, tolerability, pharmacokinetics (PK-the amount of study drug in the blood), and immunogenicity (how the study drug affects the immune system) of single dose and dose levels of an investigational drug called YQ23.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

YQ23

Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated

BIOLOGICAL

Matching Placebo

Single dose of the matching placebo delivered via intravenous route.

Sponsors & Collaborators

  • New Beta Innovation Limited

    lead INDUSTRY

Principal Investigators

  • Billy Lau, PhD · New Beta Innovation Limited

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-16
Primary Completion
2020-09-20
Completion
2020-11-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03802292 on ClinicalTrials.gov